Dihydromyricetin for Health & Longevity

Created on 11/08/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Dihydromyricetin is a plant compound sold as a dietary supplement mainly for hangovers and, increasingly, liver, metabolic and healthy-aging benefits. Its most credible signals are modest liver-test and blood sugar improvements in fatty liver disease or type 2 diabetes, from a few small, short trials. Hangover results disagree; aging findings are laboratory and animal only. Safety looks reassuring so far; open questions: medicine interactions, drowsiness with sedatives, heavier drinking. (Full Review)

Protocol

Metabolic and liver regimen
300 mg twice daily
600 mg/day for 3 months in fatty liver disease
Typical supplement range
300–1,000 mg daily
Range reported for DHM supplements
Single versus split dose
Two daily doses
Favored by the short animal half-life and twice-daily trial regimens
Time to effect
Liver enzymes
Within 3 months
In fatty liver disease
Blood glucose markers
Within 1 month
In type 2 diabetes
Hangover effects
Within hours, if any
Around the drinking occasion

Benefits

Contraindications
  • Pregnant or breastfeeding women
  • Chronic liver disease, including cirrhosis
  • Children and adolescents
  • Transplant recipients and others on narrow-margin CYP3A4 drugs
  • People with alcohol use disorder using DHM instead of treatment
Key Interactions
Theoretical (inferred from mechanism)
  • CYP3A4-cleared prescription drugs (tacrolimus, cyclosporine)
  • CYP2D6-cleared drugs (metoprolol, codeine)
  • Acetaminophen and other CYP2E1 substrates (chlorzoxazone)
  • P-gp substrates (digoxin, dabigatran)
  • Benzodiazepines and Z-drugs (diazepam, zolpidem)
  • Glucose-lowering drugs (sulfonylureas, insulin)
  • Statins (such as atorvastatin) and red yeast rice
  • Glucose-lowering supplements (berberine, chromium)
  • Sedating supplements and over-the-counter sleep aids (kava, diphenhydramine)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Liver injury; heavier drinking from milder hangovers
  • Speculative: Altered drug levels; additive sedation; off-target epigenetic effects

Monitoring

Marker Target Why
ALT 7–55 U/L Expected to fall; liver safety check
AST Not specified in the ER Paired with ALT and GGT
GGT 8–61 U/L Expected to fall
Fasting glucose 70–99 mg/dL Expected to fall; safety check with diabetes drugs
HbA1c 4.0–5.6% Expected to fall
LDL cholesterol No established target; track change from own baseline Expected to fall
Apolipoprotein B Not specified in the ER Paired with LDL cholesterol
Cystatin C 0.5–1.0 mg/L Expected to fall in type 2 diabetes
Drug trough level (tacrolimus, cyclosporine, digoxin) No established target; compare with the level before starting DHM Safety check

Cadence: Baseline panel before starting; drug levels and glucose checks at 1–2 weeks for those on interacting medicines; full panel at 3 months, then every 6–12 months while use continues

Qualitative Assessment

  • Hangover severity and next-day energy after a matched number of drinks
  • Number of drinks per week, compared with the pre-DHM baseline
  • Sleep quality and time to fall asleep
  • Daytime drowsiness, especially when combined with other calming agents
  • Digestive comfort